リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

リケラボ 全国の大学リポジトリにある学位論文・教授論文を一括検索するならリケラボ論文検索大学・研究所にある論文を検索できる

大学・研究所にある論文を検索できる 「Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine」の論文概要。リケラボ論文検索は、全国の大学リポジトリにある学位論文・教授論文を一括検索できる論文検索サービスです。
リケラボ

コピーが完了しました

URLをコピーしました

論文の公開元へ論文の公開元へ
書き出し

Association between Adverse Reactions to the First and Second Doses of COVID-19 Vaccine

Goda, Ken Kenzaka, Tsuneaki Yahata, Shinsuke Okayama, Masanobu Nishisaki, Hogara 神戸大学

2022.08

概要

This study investigated the frequency of adverse reactions to COVID-19 vaccines in Japan and the impact of first-dose adverse reactions on second-dose adverse reactions. Individuals who received an mRNA COVID-19 vaccine at our center in March or April 2021 were included. Data were collected using questionnaires. The main factors were age (<40, 40–59, and >60 years), sex, underlying disease, and first-dose adverse reaction. The primary outcomes were incidence of local and systemic adverse reactions (ARs) attributable to the vaccine. Logistic regression was used to calculate odds ratios (ORs) and 95% confidence intervals (CIs). Among 671 participants, 90% experienced local or systemic ARs. An AR to the first dose was associated with a significantly increased risk of an AR to the second dose (OR: 49.63, 95% CI: 21.96–112.16). ARs were less common among men than among women (OR: 0.36, 95% CI: 0.17–0.76). Local ARs were less common among those aged 60 years or older (OR: 0.35, 95% CI: 0.18–0.66), whereas systemic ARs were more common among those aged under 40 years. Information on ARs to the first dose is important for healthcare providers and recipients when making vaccination decisions.

論文の公開元へ

関連論文

関連論文をもっと見る

参考文献

1. Leidner, A.J.; Murthy, N.; Chesson, H.W.; Biggerstaff, M.; Stoecker, C.; Harris, A.M.; Acosta, A.; Dooling, K.; Bridges, C.B. Cost-effectiveness of adult vaccination: A systematic review. Vaccine 2019, 37, 226–234. [CrossRef]

2. Bauernfeind, S.; Hitzenbichler, F.; Huppertz, G.; Zeman, F.; Koller, M.; Schmidt, B.; Plentz, A.; Bauswein, M.; Mohr, A.; Salzberger, B. Brief report: Attitudes towards COVID-19 vaccination among hospital employees in a tertiary care university hospital in Germany in December 2020. Infection 2021, 49, 1307–1311. [CrossRef]

3. Polack, F.P.; Thomas, S.J.; Kitchin, N.; Absalon, J.; Gurtman, A.; Lockhart, S.; Perez, J.L.; Pérez Marc, G.; Moreira, E.D.; Zerbini, C.; et al. Safety and efficacy of BNT162b2 mRNA COVID-19 vaccine. N. Engl. J. Med. 2020, 383, 2603–2615. [CrossRef]

4. Teo, S.P. Review of COVID-19 mRNA vaccines: BNT162b2 and mRNA-1273. Pharm. Pract. 2021, 8971900211009650, Epub ahead of print. [CrossRef]

5. MacDonald, M.E. Vaccine hesitancy: Definition, scope, and determinants. Vaccine 2015, 33, 4161–4164. [CrossRef]

6. Kawata, K.; Nakabayashi, M. Determinants of COVID-19 vaccine preference: A survey study in Japan. SSM Popul. Health 2021, 15, 100902. [CrossRef]

7. Otani, J.; Ohta, R.; Sano, C. Association between immunoglobulin G levels and adverse effects following vaccination with the BNT162b2 vaccine among Japanese healthcare workers. Vaccines 2021, 9, 1149. [CrossRef]

8. Izumo, T.; Kuse, N.; Awano, N.; Tone, M.; Sakamoto, K.; Takada, K.; Muto, Y.; Fujimoto, K.; Saiki, A.; Ito, Y.; et al. Side effects and antibody titer transition of the BNT162b2 messenger ribonucleic acid coronavirus disease 2019 vaccine in Japan. Respir. Investig. 2021, 59, 635–642. [CrossRef]

9. Luo, C.; Liu, M.; Li, Q.; Zheng, X.; Ai, W.; Gong, F.; Fan, J.; Liu, S.; Wang, X.; Luo, J. Dynamic changes and prevalence of SARS-CoV-2 IgG/IgM antibodies: Multiple factor-based analysis. Int. J. Infect. Dis. 2021, 108, 57–62.

10. Cadorna-Carlos, J.B.; Nolan, T.; Borja-Tabora, C.F.; Santos, J.; Montalban, M.C.; de Looze, F.J.; Eizenberg, P.; Hall, S.; Dupuy, M.; Hutagalung, Y.; et al. Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized controlled phase III trial. Vaccine 2015, 33, 2485–2492. [CrossRef]

11. Watanabe, K.; Matsumoto, S.; Toyoshima, E. Adverse drug reaction following quadrivalent influenza vaccination coverage of health care workers. Jpn. J. Environ. Infect. 2016, 31, 397–401.

12. Kenzaka, T.; Yahata, S.; Goda, K.; Kumabe, A.; Kamada, M.; Okayama, M. Effects of vaccination day routine activities on influenza vaccine efficacy and vaccination-induced adverse reaction incidence: A cohort study. Vaccines 2021, 9, 753. [CrossRef]

13. Lupica, A.; Di Stefano, V.; Iacono, S.; Pignolo, A.; Quartana, M.; Gagliardo, A.; Fierro, B.; Brighina, F. Impact of COVID-19 in AChR myasthenia gravis and the safety of vaccines: Data from an Italian cohort. Neurol. Int. 2022, 14, 406–416. [CrossRef]

14. Klugar, M.; Riad, A.; Mekhemar, M.; Conrad, J.; Buchbender, M.; Howaldt, H.P.; Attia, S. Side effects of mRNA-Based and viral vector-based COVID-19 vaccines among German healthcare workers. Biology 2021, 10, 752. [CrossRef]

15. Centres for Disease Control and Prevention. Reactions and Adverse Events of Pfizer-BioNTech COVID-19 Vaccine. Available online: https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html (accessed on 7 March 2021).

16. Riad, A.; Pokorná, A.; Attia, S.; Klugarová, L.; Košcˇík, M.; Klugar, M. Prevalence of COVID-19 vaccine side effects among healthcare workers in the Czech Republic. J. Clin. Med. 2021, 10, 1428. [CrossRef]

17. Sprent, J.; King, C. COVID-19 vaccine side effects: Positive feelings about feeling bad. Sci. Immunol. 2021, 6, eabj9256. [CrossRef]

18. Bunders, M.J.; Altfeld, M. Implications of sex differences in immunity against SARS-CoV-2 pathogenesis and the design of therapeutic interventions. Immunity 2020, 53, 487–495. [CrossRef]

19. El-Shitany, N.A.; Harakeh, S.; Badr-Eldin, S.M.; Bagher, A.M.; Eid, B.; Almukadi, H.; Alghamdi, B.S.; Alahmadi, A.A.; Hassan, N.A.; Sindi, N.; et al. Minor to moderate side effects of Pfizer-BioNTech COVID-19 vaccine among Saudi residents: A retrospective cross-sectional study. Int. J. Gen. Med. 2021, 14, 1389–1401. [CrossRef]

20. Klein, S.L.; Jedlicka, A.; Pekosz, A. The Xs and Y of immune responses to viral vaccines. Lancet Infect. Dis. 2010, 10, 338–349. [CrossRef]

21. Klimek, L.; Eckrich, J.; Hagemann, J.; Casper, I.; Huppertz, J. Allergic reactions to COVID-19 vaccines: Evidence and practice- oriented approach. Internist 2021, 62, 326–332. [CrossRef]

参考文献をもっと見る

全国の大学の
卒論・修論・学位論文
を
一発検索！

この論文の関連論文を見る